Search

Your search keyword '"Atiqi, Sadaf"' showing total 22 results
Start Over Author "Atiqi, Sadaf"
22 results on '"Atiqi, Sadaf"'

1. Post-COVID condition in patients with inflammatory rheumatic diseases: a prospective cohort study in the Netherlands

Author

Boekel, Laura, Atiqi, Sadaf, Leeuw, Maureen, Hooijberg, Femke, Besten, Yaëlle R., Wartena, Rosa, Steenhuis, Maurice, Vogelzang, Erik, Webers, Casper, Boonen, Annelies, Gerritsen, Martijn, Lems, Willem F, Tas, Sander W, van Vollenhoven, Ronald F, Voskuyl, Alexandre E, van der Horst-Bruinsma, Irene, Nurmohamed, Mike, Rispens, Theo, and Wolbink, Gertjan

Published
2023
Full Text
View/download PDF

2. Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies

Author

de Jongh, Rivka, van de Sandt, Carolien, Kuijper, Lisan, Duurland, Mariel, Hagen, Ruth, van den Dijssel, Jet, Kreher, Christine, Bos, Amelie, Palomares Cabeza, Viriginia, Konijn, Veronique, Elias, George, Vallejo, Juan, van Gils, Marrit, Ashhurst, Tom, Nejentsev, Sergey, Mirfazeli, Elham, Boekel, Laura, Stalman, Eileen W, Wieske, Luuk, Hooijberg, Femke, van Dam, Koos P J, Besten, Yaëlle R, Kummer, Laura Y L, Steenhuis, Maurice, van Kempen, Zoé L E, Killestein, Joep, Volkers, Adriaan G, Tas, Sander W, van der Kooi, Anneke J, Raaphorst, Joost, Löwenberg, Mark, Takkenberg, R Bart, D'Haens, Geert R A M, Spuls, Phyllis I, Bekkenk, Marcel W, Musters, Annelie H, Post, Nicoline F, Bosma, Angela L, Hilhorst, Marc L, Vegting, Yosta, Bemelman, Frederike J, Voskuyl, Alexandre E, Broens, Bo, Parra Sanchez, Agner, van Els, Cécile A C M, de Wit, Jelle, Rutgers, Abraham, de Leeuw, Karina, Horváth, Barbara, Verschuuren, Jan J G M, Ruiter, Annabel M, van Ouwerkerk, Lotte, van der Woude, Diane, Allaart, Cornelia F, Teng, Y K Onno, van Paassen, Pieter, Busch, Matthias H, Jallah, Papay B P, Brusse, Esther, van Doorn, Pieter A, Baars, Adája E, Hijnen, Dirk Jan, Schreurs, Corine R G, van der Pol, W Ludo, Goedee, H Stephan, Vogelzang, Erik H, Leeuw, Maureen, Atiqi, Sadaf, van Vollenhoven, Ronald, Gerritsen, Martijn, van der Horst-Bruinsma, Irene E, Lems, Willem F, Nurmohamed, Mike T, Boers, Maarten, Keijzer, Sofie, Keijser, Jim, Boogaard, Arend, Cristianawati, Olvi, ten Brinke, Anja, Verstegen, Niels J M, Zwinderman, Koos A H, van Ham, S Marieke, Rispens, Theo, Kuijpers, Taco W, Wolbink, Gertjan, and Eftimov, Filip

Published
2022
Full Text
View/download PDF

4. Novel DNA methylome biomarkers associated with adalimumab response in rheumatoid arthritis patients

Author

Hageman, Ishtu, primary, Mol, Femke, additional, Atiqi, Sadaf, additional, Joustra, Vincent, additional, Sengul, Hilal, additional, Henneman, Peter, additional, Visman, Ingrid, additional, Hakvoort, Theodorus, additional, Nurmohamed, Mike, additional, Wolbink, Gertjan, additional, Levin, Evgeni, additional, Li Yim, Andrew Y.F., additional, D’Haens, Geert, additional, and de Jonge, Wouter J., additional

Published
2023
Full Text
View/download PDF

5. Using adalimumab serum concentration to choose a subsequent biological DMARD in rheumatoid arthritis patients failing adalimumab treatment (ADDORA-switch): study protocol for a fully blinded randomised superiority test-treatment trial

Author

Wientjes, Maike H. M., Atiqi, Sadaf, Wolbink, Gerrit Jan, Nurmohamed, Michael T., Boers, Maarten, Rispens, Theo, de Vries, Annick, van Vollenhoven, Ronald F., van den Bemt, Bart J. F., and den Broeder, Alfons A.

Published
2021
Full Text
View/download PDF

10. SARS-CoV-2 breakthrough infections in patients with immune-mediated inflammatory diseases during the omicron dominant period

Author

Boekel, Laura, primary, Besten, Yaëlle R, additional, Hooijberg, Femke, additional, Wartena, Rosa, additional, Steenhuis, Maurice, additional, Vogelzang, Erik, additional, Leeuw, Maureen, additional, Atiqi, Sadaf, additional, Tas, Sander W, additional, Lems, Willem F, additional, van Ham, S Marieke, additional, Eftimov, Filip, additional, Stalman, Eileen W, additional, Wieske, Luuk, additional, Kuijpers, Taco W, additional, Voskuyl, Alexandre E, additional, van Vollenhoven, Ronald F, additional, Gerritsen, Martijn, additional, Krieckaert, Charlotte, additional, Rispens, Theo, additional, Boers, Maarten, additional, Nurmohamed, Mike T, additional, and Wolbink, Gertjan, additional

Published
2022
Full Text
View/download PDF

11. Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies

Author

Boekel, Laura, primary, Stalman, Eileen W, additional, Wieske, Luuk, additional, Hooijberg, Femke, additional, van Dam, Koos P J, additional, Besten, Yaëlle R, additional, Kummer, Laura Y L, additional, Steenhuis, Maurice, additional, van Kempen, Zoé L E, additional, Killestein, Joep, additional, Volkers, Adriaan G, additional, Tas, Sander W, additional, van der Kooi, Anneke J, additional, Raaphorst, Joost, additional, Löwenberg, Mark, additional, Takkenberg, R Bart, additional, D'Haens, Geert R A M, additional, Spuls, Phyllis I, additional, Bekkenk, Marcel W, additional, Musters, Annelie H, additional, Post, Nicoline F, additional, Bosma, Angela L, additional, Hilhorst, Marc L, additional, Vegting, Yosta, additional, Bemelman, Frederike J, additional, Voskuyl, Alexandre E, additional, Broens, Bo, additional, Parra Sanchez, Agner, additional, van Els, Cécile A C M, additional, de Wit, Jelle, additional, Rutgers, Abraham, additional, de Leeuw, Karina, additional, Horváth, Barbara, additional, Verschuuren, Jan J G M, additional, Ruiter, Annabel M, additional, van Ouwerkerk, Lotte, additional, van der Woude, Diane, additional, Allaart, Cornelia F, additional, Teng, Y K Onno, additional, van Paassen, Pieter, additional, Busch, Matthias H, additional, Jallah, Papay B P, additional, Brusse, Esther, additional, van Doorn, Pieter A, additional, Baars, Adája E, additional, Hijnen, Dirk Jan, additional, Schreurs, Corine R G, additional, van der Pol, W Ludo, additional, Goedee, H Stephan, additional, Vogelzang, Erik H, additional, Leeuw, Maureen, additional, Atiqi, Sadaf, additional, van Vollenhoven, Ronald, additional, Gerritsen, Martijn, additional, van der Horst-Bruinsma, Irene E, additional, Lems, Willem F, additional, Nurmohamed, Mike T, additional, Boers, Maarten, additional, Keijzer, Sofie, additional, Keijser, Jim, additional, van de Sandt, Carolien, additional, Boogaard, Arend, additional, Cristianawati, Olvi, additional, ten Brinke, Anja, additional, Verstegen, Niels J M, additional, Zwinderman, Koos A H, additional, van Ham, S Marieke, additional, Rispens, Theo, additional, Kuijpers, Taco W, additional, Wolbink, Gertjan, additional, Eftimov, Filip, additional, de Jongh, Rivka, additional, Kuijper, Lisan, additional, Duurland, Mariel, additional, Hagen, Ruth, additional, van den Dijssel, Jet, additional, Kreher, Christine, additional, Bos, Amelie, additional, Palomares Cabeza, Viriginia, additional, Konijn, Veronique, additional, Elias, George, additional, Vallejo, Juan, additional, van Gils, Marrit, additional, Ashhurst, Tom, additional, Nejentsev, Sergey, additional, and Mirfazeli, Elham, additional

Published
2022
Full Text
View/download PDF

12. COVID-19 vaccine acceptance over time in patients with immune-mediated inflammatory rheumatic diseases

Author

Boekel, Laura, primary, Hooijberg, Femke, additional, Besten, Yaëlle R, additional, Vogelzang, Erik H, additional, Steenhuis, Maurice, additional, Leeuw, Maureen, additional, Atiqi, Sadaf, additional, van Vollenhoven, Ronald, additional, Lems, Willem F, additional, Bos, Wouter H, additional, Wijbrandts, Carla A, additional, Gerritsen, Martijn, additional, Krieckaert, Charlotte, additional, Voskuyl, Alexandre E, additional, van der Horst-Bruinsma, Irene E, additional, Tas, Sander W, additional, Boers, Maarten, additional, Rispens, Theo, additional, Nurmohamed, Michael T, additional, and Wolbink, Gertjan, additional

Published
2022
Full Text
View/download PDF

13. Antibody development and disease severity of COVID-19 in non-immunised patients with rheumatic immune-mediated inflammatory diseases: data from a prospective cohort study

Author

Boekel, Laura, primary, Hooijberg, Femke, additional, Vogelzang, Erik H, additional, Besten, Yaëlle R, additional, Leeuw, Maureen, additional, Atiqi, Sadaf, additional, van Vollenhoven, Ronald F, additional, Wijbrandts, Carla A, additional, Gerritsen, Martijn, additional, Krieckaert, C, additional, Dijkshoorn, Bas, additional, Bakhlakh, Siham, additional, Crooijmans, Juliette J, additional, Voskuyl, Alexandre, additional, van der Horst-Bruinsma, Irene E, additional, Lems, Willem, additional, Kuijpers, Taco W, additional, van Ham, S Marieke, additional, Wieske, Luuk, additional, Eftimov, Filip, additional, Kummer, Laura Y, additional, van Dam, PJ Koos, additional, Stalman, Eileen W, additional, Steenhuis, Maurice, additional, Keijzer, Sofie, additional, Cristianawati, Olvi, additional, Keijser, Jim, additional, Loeff, Floris C, additional, Tas, Sander W, additional, Nurmohamed, Michael T, additional, Boers, Maarten, additional, Rispens, Theo, additional, and Wolbink, Gertjan, additional

Published
2022
Full Text
View/download PDF

14. SARS-CoV-2 Delta Breakthrough Infections in Vaccinated Patients with Immune-Mediated Inflammatory Diseases Using Immunosuppressants – Data from Two Controlled Prospective Cohort Studies

Author

Boekel, Laura, primary, Stalman, Eileen, additional, Wieske, Luuk, additional, Hooijberg, Femke, additional, van Dam, Koos, additional, Besten, Yaëlle, additional, Kummer, Laura, additional, Steenhuis, Maurice, additional, van Kempen, Zoé, additional, Killestein, Joep, additional, Volkers, Adriaan G., additional, Tas, Sander, additional, van der Kooi, Anneke J., additional, Raaphorst, Joost, additional, Löwenberg, Mark, additional, Takkenberg, R. Bart, additional, D'Haens, Geert R.A.M., additional, Spuls, Phyllis I., additional, Bekkenk, Marcel W., additional, Musters, Annelie H., additional, Post, Nicoline F., additional, Bosma, Angela L., additional, Hilhorst, Marc L., additional, Vegting, Yosta, additional, Bemelman, Frederike J., additional, Voskuyl, Alexandre, additional, Broens, Bo, additional, Sanchez, Agner Parra, additional, van Els, Cecile, additional, de Wit, Jelle, additional, Rutgers, Abraham, additional, de Leeuw, Karina, additional, Horváth, Barbara, additional, Verschuuren, Jan J.G.M., additional, Ruiter, Annabel M., additional, van Ouwerkerk, Lotte, additional, van der Woude, Diane, additional, Allaart, Cornelia F., additional, Teng, Onno YK, additional, van Paassen, Pieter, additional, Busch, Matthias, additional, Jallah, Papay B.P., additional, Brusse, Esther, additional, van Doorn, Pieter, additional, Baars, Adája E., additional, Hijnen, Dirk Jan, additional, Schreurs, Corine R.G., additional, van der Pol, Ludo, additional, Goedee, H. Stephan, additional, Vogelzang, Erik, additional, Leeuw, Maureen, additional, Atiqi, Sadaf, additional, van Vollenhoven, Ronald, additional, Gerritsen, Martijn, additional, van der Horst-Bruinsma, Irene E., additional, Lems, Willem F., additional, Nurmohamed, Michael, additional, Boers, Maarten, additional, Keijzer, Sofie, additional, Keijser, Jim, additional, Boogaard, Arend, additional, Cristianawati, Olvi, additional, ten Brinke, Anja, additional, Verstegen, Niels, additional, Zwinderman, Aeilko H., additional, van Ham, Marieke, additional, Rispens, Theo, additional, Kuijpers, Taco, additional, Wolbink, Gertjan, additional, and Eftimov, Filip, additional

Published
2022
Full Text
View/download PDF

15. Additional file 1 of Using adalimumab serum concentration to choose a subsequent biological DMARD in rheumatoid arthritis patients failing adalimumab treatment (ADDORA-switch): study protocol for a fully blinded randomised superiority test-treatment trial

Author

Wientjes, Maike H. M., Atiqi, Sadaf, Wolbink, Gerrit Jan, Nurmohamed, Michael T., Boers, Maarten, Rispens, Theo, de Vries, Annick, van Vollenhoven, Ronald F., van den Bemt, Bart J. F., and den Broeder, Alfons A.

Abstract

Additional file 1. SPIRIT 2013 Checklist.

Published
2021
Full Text
View/download PDF

16. Antibody Development and Disease Severity of Covid-19 in Non-Immunized Patients with Rheumatic Immune-Mediated Inflammatory Diseases: Data from a Prospective Cohort Study

Author

Boekel, Laura, primary, Hooijberg, Femke, additional, Vogelzang, Erik, additional, Besten, Yaëlle, additional, Leeuw, Maureen, additional, Atiqi, Sadaf, additional, van Vollenhoven, Ronald, additional, Wijbrandts, Carla A., additional, Gerritsen, Martijn, additional, Krieckaert, Charlotte, additional, Dijkshoorn, Bas, additional, Bakhlakh, Siham, additional, Crooijmans, Julliëtte J., additional, Voskuyl, Alexandre, additional, van der Horst-Bruinsma, Irene E., additional, Lems, Willem F., additional, Kuijpers, Taco, additional, van Ham, Marieke, additional, Wieske, Luuk, additional, Eftimov, Filip, additional, Kummer, Laura, additional, van Dam, Koos, additional, Stalman, Eileen, additional, Steenhuis, Maurice, additional, Keijzer, Sofie, additional, Cristianawati, Olvi, additional, Keijser, Jim, additional, Loeff, Floris, additional, Tas, Sander, additional, Nurmohamed, Michael, additional, Boers, Maarten, additional, Rispens, Theo, additional, and Wolbink, Gertjan, additional

Published
2021
Full Text
View/download PDF

22. Changes in Tumor Necrosis Factor Inhibitor Drug Survival in Patients With Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis Over 15 Years.

Author

Visman IM, Atiqi S, Boers M, Twisk JWR, and Nurmohamed MT

Abstract

Objective: To study changes in retention of first biologic disease-modifying antirheumatic drug (DMARD) therapy over a period of 15 years in an inception cohort of patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS)., Methods: We assessed patient and disease characteristics and drug survival of patients starting a biologic (tumor necrosis factor inhibitor [TNFi]) therapy between 2004 and 2019 in routine care at the Amsterdam Rheumatology and Immunology Center, Reade, the Netherlands. Starts were classified as early (2004-2008), intermediate (2009-2013), and recent (2014-2018). Kaplan-Meier plots and log-rank tests assessed the overall difference in drug survival between the 3 observation groups and between diagnoses, followed by Cox regression to estimate hazard ratios (HRs)., Results: We included 1938 consecutive patients starting TNFi therapy, 63% with RA, 19% with PsA, and 19% with AS; 65% were female. Drug survival decreased significantly over time (overall P < 0.001), mostly caused by decreases in the most recent 4-year period. The HR for drug continuation was 2.04 (95% CI 1.71-2.43, P < 0.001) for the early vs the recent group and 1.92 (95% CI 1.58-2.35, P < 0.001) for the intermediate vs the recent group. Drug survival time was significantly different between diseases (overall P < 0.001), mostly caused by shorter survival in RA. The HR for drug continuation was 0.58 (95% CI 0.47-0.73, P < 0.001) for RA vs PsA and 0.63 (95% CI 0.51-0.78, P < 0.001) for RA vs AS., Conclusion: Patients with RA, PsA, and AS currently initiating biologic (TNFi) therapy discontinue the drug much sooner than those starting shortly after the drugs were introduced. This is most likely because of the availability of alternative novel biologic and targeted synthetic DMARD treatments and treat-to-target protocols enabling and necessitating earlier switching.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results